Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Newly Merged Wholesaler Koyo to Get No. 3 Share in Shikoku
April 1, 2002
- 26th JMC General Assembly to Invite Citizens to Participate
April 1, 2002
- Yamanouchi Ties Up with Metabolex for Discovering Diabetes Drugs
April 1, 2002
- Nikken Chemicals to Focus on Drugs
April 1, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 1, 2002
- Sawai Sees 23.48% Reduction in NHI Prices
April 1, 2002
- Only 10-20% of Patients with Osteoporosis Receiving Treatment: WLJ Seminar
April 1, 2002
- Taiyo to Start Strategy to Promote Use of Generics
April 1, 2002
- JACCRO Established to Promote Clinical Trials for Cancer
April 1, 2002
- BUSINESS NEWS IN BRIEF
April 1, 2002
- RenaScience Offers Renal Disease-Related Genes to Companies
April 1, 2002
- Pele Appointed as Japan's Educational Ambassador for ED: Pfizer
April 1, 2002
- Utilization of Medicinal Plants Reported by Korosho
April 1, 2002
- Our Growth Not Enough for Survival: Mr Yokotsuka of Sumitomo
April 1, 2002
- PMS Measures to Be Strengthened in PAL Amendment
April 1, 2002
- Kansai Bio Conference in Kobe Focuses on Regenerative Medicine
April 1, 2002
- DIAGNOSTIC NEWS IN BRIEF
April 1, 2002
- Ono's Elaspol Recommended for Approval by CDFS Department
April 1, 2002
- Makers Are Not Supplying Sufficient Information to Pharmacies: Survey
April 1, 2002
- Meiji Licenses Carbapenem from Wyeth Lederle
April 1, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…